Cencora, Inc. Common Stock (COR)

Healthcare distributor Cencora (NYSECOR) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 12.8% year on year to $81.49 billion. Its non-GAAP profit of $3.73 per share was 6% above analysts’ consensus estimates.

Wall Street rose on Wednesday, with all major equity indices advancing as investors assessed the latest batch of corporate earnings and drew optimism from positive labor market data.

Cencora posted Q1 sales of $81.5 billion, exceeding forecasts, with strong GLP-1 drug sales. Adjusted EPS beat estimates, and FY25 guidance was raised.

JMP Securities analyst Ronald Josey maintained Lemonade with a Market Outperform and raised the price target from $40 to $60.

The Relative Strength (RS) Rating for McKesson stock jumped into a new percentile Wednesday, as it got a lift from 70 to 75.

In a welcome move, Cardinal Health stock saw its Relative Strength (RS) Rating rise from 65 to 71 on Friday.

An “everything rally” powered Wall Street on Wednesday after the 2024 election results, with Donald Trump emerging as the clear presidential winner.

Cencora will potentially pay up to $500 million in aggregate contingent consideration in fiscal years 2027 and 2028.

10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90%